KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Net Margin (2016 - 2025)

Historic Net Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 40.17%.

  • Rigel Pharmaceuticals' Net Margin rose 177100.0% to 40.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.15%, marking a year-over-year increase of 376800.0%. This contributed to the annual value of 9.74% for FY2024, which is 312100.0% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Net Margin stood at 40.17%, which was up 177100.0% from 58.63% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Net Margin registered a high of 58.63% during Q2 2025, and its lowest value of 164.0% during Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median Net Margin value was 20.23% (recorded in 2023), while the average stood at 24.27%.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Net Margin was 1135000bps (2022), while the steepest drop was -2127500bps (2022).
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Net Margin stood at 110.76% in 2021, then surged by 102bps to 2.73% in 2022, then dropped by -25bps to 2.06% in 2023, then skyrocketed by 1108bps to 24.87% in 2024, then surged by 62bps to 40.17% in 2025.
  • Its Net Margin stands at 40.17% for Q3 2025, versus 58.63% for Q2 2025 and 21.4% for Q1 2025.